Accessibility Menu
Natera logo

Natera

(NASDAQ) NTRA

Current Price$271.51
Market Cap$38.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)+1,093%
5 Year+140%
1 Year+89%
1 Month+20%
Natera last closing stock price
MetricPriceDate
Last closeUSD 271.392026-07-17
Natera stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.53%USD 269.952026-07-10
1 month+19.85%USD 226.442026-06-17
3 month+30.23%USD 208.402026-04-17
Year to date+18.46%USD 229.092025-12-31
1 year+89.28%USD 143.382025-07-17
3 year+457.61%USD 48.672023-07-18
5 year+139.91%USD 113.122021-07-16
Since inception+1,093.45%USD 22.742015-07-02

Natera Financials at a Glance

Market Cap

$38.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.50B

Net Income (TTM)

-$226.32M

EPS (TTM)

-$1.64

P/E Ratio

-165.35

Dividend

$0.00

Beta (Volatility)

1.41 (Average)

Price

$271.51

Volume

1,014,525

Open

$265.40

Previous Close

$271.39

Daily Range

$262.00 - $272.31

52-Week Range

$131.81 - $288.04

Estimated Earnings Date

Aug 6, 2026

NTRA News

Stanley Druckenmiller_Duquesne Family Office_Chairman_imageSource_Getty Images

Billionaire Stanley Druckenmiller's Top Holding Isn't Nvidia. Instead, It's This Under-the-Radar Stock That Wall Street Loves.

Jack DelaneyJul 16, 2026
biopharma research and testing

Here's Billionaire Stanley Druckenmiller's Top Holding (Hint: It's Not Alphabet or Nvidia)

James BrumleyJun 3, 2026
Doctor holding clipboard stands with virtual DNA double helix in the air near him.

Best Genomics Stocks for 2026 and How to Invest

Lyle DalyApr 18, 2026
A biotech lab technician using multiple pipettes to load blood samples into test tubes.

How to Invest in iShares Biotechnology ETF (IBB)

Tony DongFeb 25, 2026
Biotech scientist working on a tablet with bio-related icons projected above it.

How to Invest in VanEck Biotech ETF (BBH)

Tony DongFeb 25, 2026
Foolcom-Featured.png

Natera (NTRA) Q2 Revenue Jumps 32%

Motley Fool Markets TeamAug 7, 2025
Boardroom 2

27.5% of Stanley Druckenmiller's $3.7 Billion Portfolio Is Invested in These 3 Under-the-Radar AI Stocks

Bram BerkowitzApr 7, 2025
scientist altering DNA genome project

Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings

Stefon WaltersMar 19, 2025
Page 1

NTRA: Motley Fool Moneyball Superscore

80

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Natera

Natera helps doctors find genetic issues by looking at tiny bits of DNA in blood samples. Its tests help families plan for babies and help doctors watch for cancer or organ rejection. These tools make it easier to find and treat diseases early without needing surgery.

The Product Menu

  • Oncology: Personalized blood tests like Signatera and Latitude detect cancer traces and monitor treatment response for solid tumors.
  • Women’s Health: Prenatal tests such as Panorama and Horizon screen for fetal genetic conditions and carrier status from a simple blood draw.
  • Organ Health: Tests including Prospera measure donor DNA in a recipient's blood to check for heart, lung, or kidney transplant rejection.
  • Cloud Software: The Constellation platform lets global laboratories use the company's complex math and algorithms to run tests locally.

New Moves and Big Steps

  • Acquired Foresight Diagnostics, Inc. in December 2025 to add new cancer monitoring technology and enter the lymphoma market.
  • Launched Fetal Focus to screen for single-gene conditions when a partner is not available for testing.
  • Introduced the Fetal RhD test to help pregnant patients avoid unnecessary medicine based on their baby's blood type.
  • Expanded the Signatera platform to include coverage for advanced ovarian cancer and monitoring for all solid tumors treated with immunotherapy.

What Makes Natera Different

The company stands out by using complex math to find tiny amounts of DNA in blood, which are as small as a single cell. It reaches patients through a direct sales team and a global network of over 100 laboratory and distribution partners.

A Look at the Numbers

  • Revenue reached $665.5 million in Q4 2025, up 39.8% from Q4 2024.
  • Net income rose to $47.3 million in Q4 2025, up 187.9% year-over-year.
  • Free cash flow grew to $37.8 million in Q4 2025, an 8.8% increase from the previous year.
  • Annual test volume grew to 3.5 million tests in 2025, compared to 3.1 million in 2024.
  • Gross profit hit $446.8 million in Q4 2025, up 49.1% from Q4 2024.

Bottom Line

Natera has transformed from a prenatal testing specialist into a broad diagnostics business covering cancer and organ health. Its growth is driven by a unique technology platform and a commitment to clinical validation through hundreds of peer-reviewed studies.

AI Generated • Apr 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

6,140

CEO

Stephen Leonard Chapman

Website

www.natera.com

Headquarters

Austin, TX 78753, US

NTRA Financials

Key Financial Metrics (TTM)

Gross Margin

65.16%

Operating Margin

-12.97%

Net Income Margin

-9.05%

Return on Equity

-15.13%

Return on Capital

-16.08%

Return on Assets

-8.66%

Earnings Yield

-0.60%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$38.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

143.22M

Volume

1.01M

Avg. Volume

1.54M

Financials (TTM)

Gross Profit

$1.63B

Operating Income

-$324.25M

EBITDA

-$223.76M

Operating Cash Flow

$211.02M

Capital Expenditure

-$119.01M

Free Cash Flow

$92.01M

Cash & ST Invst.

$1.09B

Total Debt

$240.08M

Natera Performance Analysis

Natera annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 820,222,00031.1%
20232023-12-31USD 1,082,571,00032.0%
20242024-12-31USD 1,696,911,00056.7%
20252025-12-31USD 2,306,113,00035.9%
Natera sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-308.9%
Q32025-09-308.3%
Q42025-12-3112.4%
Q12026-03-314.7%
Natera annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -5.576.9%
20232023-12-31USD -3.78-32.1%
20242024-12-31USD -1.53-59.6%
20252025-12-31USD -1.52-0.3%
Natera sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-48.0%
Q32025-09-3013.5%
Q42025-12-31154.7%
Q12026-03-31-271.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$696.64M

+38.8%

Gross Profit

$451.44M

+42.3%

Gross Margin

64.80%

N/A

Market Cap

$38.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.33M

N/A

Employees

6,140

N/A

Net Income

-$85.09M

-27.1%

EBITDA

-$65.47M

-15.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.09B

+9.7%

Total Debt

$240.08M

+22.7%

Accounts Receivable

$417.60M

+31.2%

Inventory

$70.72M

+40.4%

Long Term Debt

$144.95M

+40.7%

Short Term Debt

$95.13M

+2.8%

Return on Assets

-8.66%

N/A

Return on Invested Capital

-15.77%

N/A

Free Cash Flow

$18.03M

-20.3%

Operating Cash Flow

$40.17M

-9.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TEVATeva Pharmaceutical Industries Limited
$32.03-0.59%
IQVIQVIA Holdings Inc.
$206.26-2.01%
DXCMDexCom, Inc.
$76.65-1.71%
ILMNIllumina, Inc.
$186.65-1.89%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
AALAmerican Airlines Group
$14.98-0.04%
INTCIntel
$95.04-0.02%
NOKNokia
$10.12-0.03%

Questions About NTRA

What is the current price of Natera?

Natera is trading at $271.39 per share.

What is the 52-week range for Natera?

Over the past 52 weeks, Natera has traded between $131.81 and $288.04.

How much debt does Natera have?

As of the most recent reporting period, Natera reported total debt of $240.08M.

How much cash does Natera have on hand?

Natera reported $1.09B in cash and cash equivalents in its most recent financial results.

What is Natera’s dividend yield?

Natera does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services